Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bezuclastinib in advanced systemic mastocytosis
NL-OMON53808Phase 2Not yet recruiting
- Sponsor
- Cogent Biosciences
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bezuclastinib in systemic mastocytosis (SM), mast cell leukemia (MCL), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and 1 more (6 arms), sponsored by Cogent Biosciences. Primary endpoints: Safety assessments and dose modifications, Pharmacokinetics and pharmacodynamic assessments and 1 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)mast cell leukemia (MCL)systemic mastocytosis with associated hematological neoplasm (SM-AHN)Aggressive Systemic Mastocytosis (ASM)
Beyond the preview
Go deeper on NL-OMON53808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53808.